Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Acute myelocytic myelogenous leukemia AML )
424 results
  • VEGFC Antibody Therapy Drives Differentiation of AML. [Journal Article]
  • CRCancer Res 2018 Oct 15; 78(20):5940-5948
  • Kampen KR, Scherpen FJG, … De Bont ESJM
  • High expression of VEGFC predicts adverse prognosis in acute myeloid leukemia (AML). We therefore explored VEGFC-targeting efficacy as an AML therapy using a VEGFC mAb. VEGFC antibody therapy enforce...
  • [Clinical Efficacy of NOPHO-AML 2004 Regimen for Treatment of Children with Acute Myelocytic Leukemia (Non-M3)]. [Journal Article]
  • ZSZhongguo Shi Yan Xue Ye Xue Za Zhi 2018; 26(2):375-381
  • Qiu KY, Liao XY, … Zhou DH
  • CONCLUSIONS: NOPHO-AML 2004 chemotherapy regimen has high response rate and good tolerance, early treatment response is an important factor influencing prognosis. Age and repeated red blood cell infusions are the important factors influencing the prognosis, which promote bone marrow recurrence in AML children. For the children suffered from clinical high-risk AML, the NOPHO-AML 2004 chemotherapy regimen combined with HSCT can improve the prognosis of patients.
New Search Next